Nuchev Pty Ltd (AU:NUC)
ASX:NUC
Want to see AU:NUC full AI Analyst Report?
Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.11
▼(-7.50% Downside)
Action:Reiterated
Date:05/08/26
The score is primarily constrained by weak financial performance—ongoing unprofitability and negative operating/free cash flow—despite strong revenue growth and low leverage. Technicals also remain bearish with the stock trading below major moving averages, while valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Revenue Growth
Sustained ~45% revenue growth indicates durable demand for core products and successful distribution scale. Over 2–6 months this momentum supports unit economics improvement, provides operating leverage potential, and creates a larger base to pursue margin recovery if cost structure is addressed.
Negative Factors
Persistent Unprofitability
Ongoing negative EBIT and net margins indicate the business is not yet generating operating profits from its sales base. Over the medium term this limits retained earnings, constrains reinvestment capacity, and increases reliance on external capital to sustain growth and operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~45% revenue growth indicates durable demand for core products and successful distribution scale. Over 2–6 months this momentum supports unit economics improvement, provides operating leverage potential, and creates a larger base to pursue margin recovery if cost structure is addressed.
Read all positive factors
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$21.95M
Dividend YieldN/A
Average Volume (3M)7.76K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth53.69%
EPS Growth45.24%
CountryAU
Employees100
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.04
Shares Outstanding156,818,770
10 Day Avg. Volume3,027
30 Day Avg. Volume7,761
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.82
Price to Sales (P/S)0.89
P/FCF Ratio-5.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nuchev Pty Ltd Business Overview & Revenue Model
Company Description
Nuchev Limited, a health and nutrition solutions company, produces, markets, and sells goat milk-based infant formula and nutritional products to consumers in Australia, China, and Vietnam. The company provides toddler nutrition, goat nutritional ...
How the Company Makes Money
Nuchev makes money by selling branded consumer health products—primarily Olli-branded probiotic and nutritional supplement products—through a mix of wholesale and direct-to-consumer channels. Revenue is generated when Nuchev supplies inventory to ...
Nuchev Pty Ltd Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.27M | 22.94M | 11.34M | 8.79M | 9.72M | 10.90M |
| Gross Profit | 7.17M | 10.86M | 3.63M | 1.90M | 2.78M | 3.20M |
| EBITDA | -4.18M | -3.73M | -7.18M | -8.57M | -10.88M | -12.40M |
| Net Income | -4.58M | -3.82M | -7.32M | -8.81M | -11.11M | -13.27M |
Balance Sheet | ||||||
| Total Assets | 17.39M | 17.39M | 20.09M | 15.32M | 17.75M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 3.11M | 3.61M | 7.61M | 7.49M | 5.13M | 14.53M |
| Total Debt | 529.14K | 392.63K | 322.85K | 284.14K | 154.12K | 286.33K |
| Total Liabilities | 6.63M | 6.16M | 5.34M | 2.51M | 1.92M | 1.62M |
| Stockholders Equity | 10.76M | 11.23M | 14.75M | 12.82M | 15.83M | 26.69M |
Cash Flow | ||||||
| Free Cash Flow | -3.62M | -3.93M | -3.74M | -3.38M | -11.62M | -9.86M |
| Operating Cash Flow | -3.48M | -3.74M | -3.73M | -3.26M | -11.61M | -9.49M |
| Investing Cash Flow | -169.48K | -138.16K | -2.19M | -126.83K | -914.20K | 411.90K |
| Financing Cash Flow | 1.81M | -115.53K | 6.06M | 5.78M | -118.28K | 14.16M |
Nuchev Pty Ltd Technical Analysis
Neutral
0.12
Price Trends
0.13
Positive
0.14
Positive
0.14
Negative
Market Momentum
<0.01
Positive
49.91
Neutral
27.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NUC, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.13, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.91 is Neutral, neither overbought nor oversold. The STOCH value of 27.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:NUC.
Nuchev Pty Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$35.39M | 22.20 | -53.68% | ― | -12.46% | 44.05% | |
43 Neutral | AU$21.95M | -2.06 | -41.69% | ― | 53.69% | 45.24% | |
40 Underperform | AU$27.71M | -0.37 | 19.78% | ― | 6.22% | 39.68% | |
40 Underperform | AU$19.08M | -5.27 | -19.17% | ― | 44.25% | 41.58% | |
39 Underperform | AU$5.48M | -0.92 | -92.72% | ― | 5.79% | 29.75% |
* Consumer Defensive Sector Average
AU:NUC
Nuchev Pty Ltd
0.14
-0.08
-37.78%
AU:NOU
Noumi Limited
0.10
-0.06
-37.50%
AU:AHF
Australian Dairy Nutritionals Group
0.02
-0.02
-46.34%
AU:WNX
Wellnex Life Ltd
0.08
-0.20
-72.22%
AU:MBH
Maggie Beer Holdings Ltd.
0.08
0.03
46.30%
Nuchev Pty Ltd Corporate Events
Nuchev Updates Securities Dealing Policy to Strengthen Governance
May 1, 2026
Nuchev Limited has amended its Securities Dealing Policy, effective 30 April 2026, in line with ASX Listing Rule 12.10 requirements, with the updated policy formally approved by the company’s board. The change reflects ongoing governance and...
Nuchev Confirms Matthew Parker as Permanent CFO to Support Growth Strategy
May 1, 2026
Nuchev Limited has confirmed the permanent appointment of Matthew Parker as Chief Financial Officer, effective 1 May 2026, following his six-month tenure as interim CFO that began in January. The board and management cited his strong immediate imp...
Nuchev Posts Quarterly Cash Burn as Operating Outflows Outpace Receipts
Apr 27, 2026
Nuchev Limited reported receipts from customers of A$4.2 million for the March quarter, but operating cash outflows across manufacturing, marketing, staff and corporate costs resulted in a net operating cash burn of A$2.9 million. After minimal in...
Nuchev Issues 767,442 Unquoted Share Rights Under Employee Incentive Plan
Mar 20, 2026
Nuchev Limited has notified the market of the issue of 767,442 unquoted share rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on 16 March 2026 and reflect the company̵...
Nuchev shifts to full distribution model with H&S to boost margins and scale
Mar 3, 2026
Nuchev has entered a distribution agreement with HS Global to expand its role across the Brauer, Skin Physics and Rapid Loss brands, shifting from an agency-style arrangement to a full distribution model. The move gives Nuchev greater control over...
Nuchev Reaffirms Brand-Led Strategy in Half-Year Update
Feb 24, 2026
Nuchev Limited has reiterated its strategy of building trusted nutrition brands that families can rely on across multiple life stages, highlighting a disciplined focus on science-based product development and high product quality. The company unde...
Nuchev lifts revenue but widens loss as investment in goat milk nutrition growth continues
Feb 24, 2026
Nuchev reported a 12% rise in half-year revenue to $12.4 million and higher gross profit, driven mainly by its Australian retail channel and supported by practitioner and international markets, despite timing variability in shipments to Vietnam an...
Nuchev Grows Revenue but Half-Year Loss Deepens as Asset Base Thins
Feb 24, 2026
Nuchev Limited has reported a 12% increase in revenue to $12.38 million for the half-year ended 31 December 2025, but its net loss after tax widened by 48.2% to $2.34 million, reflecting higher costs or investment outlays despite growing sales. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.